Status:
COMPLETED
48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety
Lead Sponsor:
AstraZeneca
Conditions:
Dyslipidaemia
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess the efficacy and safety of rosuvastatin in reducing low density lipoprotein cholesterol levels to internationally recognised goals in subjects with dyslipidaemia...
Eligibility Criteria
Inclusion
- Fasting low density lipoprotein level as defined by the protocol.
- Fasting triglyceride level as defined by the protocol.
Exclusion
- The use of lipid lowering drugs or dietary supplements after Visit 1.
- Active arterial disease eg Unstable angina, or recent arterial surgery.
- Blood lipid levels above the limits defined in the protocol.
- Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse.
Key Trial Info
Start Date :
February 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2004
Estimated Enrollment :
1500 Patients enrolled
Trial Details
Trial ID
NCT00654602
Start Date
February 1 2002
End Date
November 1 2004
Last Update
May 28 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.